Mathematical simulations for bioanalytical assay development: The (un-)necessity and (im-)possibility of free drug quantification

Bioanalysis

Volumn 4, Issue 4, 2012, Pages 381-395

  Staack, Roland F ^a   Jordan, Gregor ^a   Heinrich, Julia ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ANALYTIC METHOD; BINDING AFFINITY; BIOASSAY; CALIBRATION; CONCENTRATION (PARAMETERS); DILUTION; DRUG DETERMINATION; DRUG RESEARCH; DRUG TARGETING; LIGAND BINDING; MATHEMATICAL MODEL; MOLECULAR INTERACTION; PROCESS DEVELOPMENT; REVIEW; SIMULATION;

ANTIBODIES, MONOCLONAL; BIOLOGICAL ASSAY; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; HUMANS; LIGANDS; MODELS, BIOLOGICAL; RESEARCH DESIGN;

EID: 84858029249     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.321     Document Type: Review

References (24)

1. Lee JW, Kelley M, King LE et al. Bioanalytical approaches to quantify 'total' and 'free' therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2011). White Paper on 'total-versus-free' bioanalysis of therapeutic proteins. Very informative and an excellent introduction into the topic.
2. Kuang B, King L, Wang HF. Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2(6), 1125-1140 (2010). Review on the bioanalytical methods used in supporting the clinical development of the US FDA approved therapeutic monoclonal antibodies.
3. Yang J, Quarmby V. Free versus total ligand-binding assays: points to consider in biotherapeutic drug development. Bioanalysis 3(11), 1163-1165 (2011).
4. Roskos LK, Schneider A, Vainshtein I et al. PK-PD modeling of protein drugs: implications in assay development. Bioanalysis 3(6), 659-675 (2011).
5. Ahene AB. Application and interpretation of free and total drug measurements in the development of biologics. Bioanalysis 3(11), 1287-1295 (2011).
6. Tang C, Prueksaritanont T. Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target. Pharm. Res. 28(10), 2447-2457 (2011).
7. Staack RF, Stracke JO, Stubenrauch K, Vogel R, Schleypen J, Papadimitriou A. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. Bioanalysis 3(5), 523-534 (2011).
8. Rup B, O'Hara D. Critical ligand-binding reagent preparation/selection: when specificity depends on reagents. AAPSJ. 9(2), E148-E155 (2007).
9. Kelley M, DeSilva B. Key elements of bioanalytical method validation for macromolecules. AAPSJ. 9(2), E156-E163 (2007).
10. Smolec J, DeSilva B, Smith W et al. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm. Res. 22(9), 1425-1431 (2005).
11. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003).
12. US FDA. Guidance for Industry: Bioanalytical Method Validation (2001).
13. Teppo AM, Maury CP. Radioimmunoassay of tumor necrosis factor in serum. Clin. Chem. 33(11), 2024-2027 (1987).
14. Lee JS, Joo IS, Seok JI. Widely varying TNF-α levels in patients with myasthenia gravis. Neurol. Sci. 30(3), 259-262 (2009).
15. Jia HY, Du J, Zhu SH et al. The roles of serum IL-18, IL-10, TNF-α and sIL-2R in patients with chronic hepatitis C. Hepatobiliary Pancreat. Dis. Int. 1(3), 378-382 (2002).
16. Arican O, Aral M, Sasmaz S et al. Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators. Inflamm. (5), 273-279 (2005).
17. Kraft A, Weindel K, Ochs A et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85(1), 178-187 (1999).
18. Kido Y. Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer. Kurume Med. J. 48(1), 43-47 (2001).
19. Hudelist G, Köstler WJ, Gschwantler-Kaulich D et al. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Eur. J. Cancer 42(2), 186-192 (2006).
20. Choi JH, Oh JY, Ryu SK et al. Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer 79(10), 1879-1883 (1997).
21. Baron AT, Baron AT, Cora EM, Lafky JM et al. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 12(2), 103-113 (2003).
22. Lemos-González Y, Rodríguez-Berrocal FJ, Cordero OJ, Gómez C, Páez de la Cadena M. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small-cell lung cancer and head and neck carcinoma. Br. J. Cancer 96(10), 1569-1578 (2007).
23. Findlay JW, Smith WC, Lee JW et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21(6), 1249-1273 (2000).
24. Lee JW. Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics. Bioanalysis 1(8), 1461-1474 (2009).